Emcure Pharmaceuticals has received approval from India’s drug regulator to market Poviztra for the treatment of fatty liver disease, marking a key expansion for the company’s semaglutide-based brand in India. The approval covers non-cirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, in adults with moderate to advanced liver fibrosis.
The company said the clearance follows the Central Drugs Standard Control Organisation’s approval of Wegovy for this indication, making semaglutide the first and only GLP-1 receptor agonist approved in India for MASH. Poviztra is a co-marketed brand of innovator semaglutide and is manufactured and imported from Novo Nordisk’s European facility.
Emcure said the new approval will allow it and its subsidiaries to expand access to the therapy for patients living with a progressive liver disease that has few treatment options. The move also extends the company’s partnership with Novo Nordisk in India, following the two companies’ announcement of Poviztra last year as Wegovy’s second brand.
Satish Mehta, CEO and MD of Emcure Pharmaceuticals, said the approval for MASH is an important milestone for patients living with a serious and often underdiagnosed liver disease. He said the development reinforces the company’s focus on bringing evidence-based treatment options to patients who need them most.
The approval adds momentum to the growing use of semaglutide beyond diabetes and weight management, as drugmakers increasingly position the molecule for broader metabolic health indications. Emcure’s launch is expected to widen awareness and access in a disease area where diagnosis and treatment have historically remained limited.
